Catalyst Funds Management Pty LTD Bio Xcel Therapeutics, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 5,200 shares of BTAI stock, worth $3,224. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,200Holding current value
$3,224% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BTAI
# of Institutions
57Shares Held
3.35MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$744,8530.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$273,2240.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$184,7860.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$114,7350.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$80,5180.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $17.4M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...